Trial Profile
A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs AZD 5634 (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 12 Jul 2018 Status changed from active, no longer recruiting to completed.
- 12 Apr 2018 Planned End Date changed from 30 Mar 2018 to 12 Apr 2018.
- 12 Apr 2018 Planned primary completion date changed from 30 Mar 2018 to 12 Apr 2018.